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prior antipsychotics, and prior use of second line treat-
ments were greater for olanzapine users, while percent
with any prior antipsychotic use was not significantly
different. Within schizophrenia, olanzapine users were
more likely to be male, have earlier age of onset, and lower
mean age. Most schizophrenia-specific studies included
no baseline service utilization or clinical measures; how-
ever, one study showed higher previous hospital costs for
olanzapine-treated patients. CONCLUSIONS: Mean age,
gender, diagnosis, age at onset, history of antipsychotic
use and prior costs differed for olanzapine- and risperi-
done-treated patients, with olanzapine-treated patients
having a history indicative of higher cost and treatment-
failure. Non-randomized studies must address these fac-
tors to avoid misleading interpretations of their results.
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The development of evidence-based practice guidelines
should be informed by the best evidence regarding the
quality and efficiency of care. Rigorous economic and
cost-effectiveness analyses provide relevant information
about the efficiency of care. OBJECTIVE: We sought to
determine the extent to which economic analyses are con-
sidered in the guideline development process. METHODS:
Using acute myocardial infarction as a sample condition,
we performed a systematic review of the published litera-
ture from 1996–1999 for national/international guide-
lines (e.g. AHA, ACC, ACP) and from 1990–1998 for
economic analyses. Economic analyses were first assessed
for methodologic quality using a structured scoring sys-
tem with high quality analyses scoring 70% or above. In-
clusion criteria were economic analyses that 1) predated
guideline publication by one or more years, and 2) as-
sessed interventions relevant to the guideline topics. A
matrix was constructed to determine the potential inclu-
sion of economic analyses in guidelines according to
these criteria. Two independent reviewers evaluated the
text and references of each guideline to quantify actual
inclusion. RESULTS: Six guidelines and 30 economic
analyses (17 high quality) were identified. Although the
30 analyses merited inclusion across the 6 guidelines in
94 instances, text mention occurred only 4% (4/94) of
the time and referencing occurred only 10% (9/94) of the
time. Similarly, the 17 high quality analyses merited in-
clusion in 61 instances but text mentions and referencing
were 3% (2/61) and 7% (4/61), respectively. Fifty per-
cent (3/6) of the guidelines mentioned at least one eco-
nomic analysis in the text and 67% (4/6) referenced at
least one; results for high quality analyses were 17% (1/6)
and 50% (3/6), respectively. CONCLUSION: Rigorous
economic analyses are infrequently considered in the de-
velopment of prestigious national guidelines. A system-
atic approach should be developed to ensure the compre-
hensive consideration of all relevant economic analyses in
the guideline development process.
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AD is a progressive disease with a large impact on health
care resources and health-related quality of life. How-
ever, in many clinical trials, health state utilities have not
been measured. OBJECTIVES: To determine a method
of deriving utility changes from efficacy outcome scales
in AD suitable for cost-effectiveness analysis. METH-
ODS: As an example of cognitive enhancer therapy, data
from the metrifonate in AD Trial (MALT), involving 393
patients, was used for outcome data. Utilities were esti-
mated by using selected subscales and mapping them to
equivalent Health Utilities Index Mark III (HUI:3) items.
The domains of ‘emotion’, ‘cognition’ and ‘self-care’
were mapped from their respective equivalent on the
Neuropsychiatric Inventory Scale and Global Deteriora-
tion Scale. Other HUI:3 domains were non-contributory
and were scored as 1’. Changes in utility from baseline to
6 months post-treatment were quantified using each
HUI:3 mapped subscale score. RESULTS: Drug im-
proved cognition, emotion and independence, and re-
duced behavioral disorders. The calculated utilities dis-
criminated between drug and placebo at 6 months (mean
utility change  0.028 and 0.023, respectively, P 
0.01). Also, it discriminated between AD stages (mild mi-
nus moderate  0.056) and between presence and ab-
sence of behavioural disorders (difference  0.16 [mild
AD] and 0.18 [moderate AD]). The significant changes in
cognition and behaviors therefore translated into a mod-
erate gain in utility (0.051) with drug over 6 months.
CONCLUSIONS: Mapping treatment outcome scales to
HUI:3 can be used successfully to derive a measure of
health utility change. This method may be implemented
in cost-effectiveness analysis. Currently, metrifonate is
under active review by regulatory bodies.
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